| Tbio | Cadherin EGF LAG seven-pass G-type receptor 1 |
Receptor that may have an important role in cell/cell signaling during nervous system formation.
The protein encoded by this gene is a member of the flamingo subfamily, part of the cadherin superfamily. The flamingo subfamily consists of nonclassic-type cadherins; a subpopulation that does not interact with catenins. The flamingo cadherins are located at the plasma membrane and have nine cadherin domains, seven epidermal growth factor-like repeats and two laminin A G-type repeats in their ectodomain. They also have seven transmembrane domains, a characteristic unique to this subfamily. It is postulated that these proteins are receptors involved in contact-mediated communication, with cadherin domains acting as homophilic binding regions and the EGF-like domains involved in cell adhesion and receptor-ligand interactions. This particular member is a developmentally regulated, neural-specific gene which plays an unspecified role in early embryogenesis. [provided by RefSeq, Jul 2008]
The protein encoded by this gene is a member of the flamingo subfamily, part of the cadherin superfamily. The flamingo subfamily consists of nonclassic-type cadherins; a subpopulation that does not interact with catenins. The flamingo cadherins are located at the plasma membrane and have nine cadherin domains, seven epidermal growth factor-like repeats and two laminin A G-type repeats in their ectodomain. They also have seven transmembrane domains, a characteristic unique to this subfamily. It is postulated that these proteins are receptors involved in contact-mediated communication, with cadherin domains acting as homophilic binding regions and the EGF-like domains involved in cell adhesion and receptor-ligand interactions. This particular member is a developmentally regulated, neural-specific gene which plays an unspecified role in early embryogenesis. [provided by RefSeq, Jul 2008]
Comments
| Disease | Target Count |
|---|---|
| Neural Tube Defects, Susceptibility to | 8 |
| Schizophrenia | 1160 |
| Schizophrenia, Catatonic | 4 |
| Disease | Target Count | P-value |
|---|---|---|
| lung carcinoma | 2843 | 2.4e-23 |
| ependymoma | 4679 | 6.8e-14 |
| malignant mesothelioma | 3232 | 1.5e-09 |
| pancreatic cancer | 2398 | 5.2e-06 |
| pediatric high grade glioma | 1064 | 1.5e-05 |
| osteosarcoma | 7950 | 2.5e-05 |
| Chronic Lymphocytic Leukemia | 262 | 3.1e-05 |
| psoriasis | 6694 | 7.2e-05 |
| pituitary cancer | 1972 | 1.0e-04 |
| lung cancer | 4740 | 1.7e-04 |
| atypical teratoid / rhabdoid tumor | 5112 | 2.8e-04 |
| breast carcinoma | 1638 | 3.6e-04 |
| glioblastoma | 5792 | 6.0e-04 |
| intraductal papillary-mucinous neoplasm (IPMN) | 3291 | 1.4e-03 |
| ductal carcinoma in situ | 1745 | 2.1e-03 |
| active Crohn's disease | 922 | 5.0e-03 |
| invasive ductal carcinoma | 2951 | 6.0e-03 |
| subependymal giant cell astrocytoma | 2287 | 1.9e-02 |
| fibroadenoma | 559 | 2.4e-02 |
| Breast cancer | 3578 | 4.3e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| spina bifida | 1074 | 4.131 | 2.1 |
| Hereditary lymphedema | 2 | 3.427 | 1.7 |
| Anencephaly | 26 | 3.348 | 1.7 |
| Disease | Target Count |
|---|---|
| Bladder exstrophy | 32 |
| Disease | log2 FC | p |
|---|---|---|
| Breast cancer | 2.400 | 4.3e-02 |
| active Crohn's disease | 1.121 | 5.0e-03 |
| atypical teratoid / rhabdoid tumor | 1.800 | 2.8e-04 |
| breast carcinoma | 1.700 | 3.6e-04 |
| Chronic Lymphocytic Leukemia | 1.457 | 3.1e-05 |
| ductal carcinoma in situ | 1.800 | 2.1e-03 |
| ependymoma | 3.500 | 6.8e-14 |
| fibroadenoma | 1.200 | 2.4e-02 |
| glioblastoma | 1.600 | 6.0e-04 |
| intraductal papillary-mucinous neoplasm ... | 1.500 | 1.4e-03 |
| invasive ductal carcinoma | 1.600 | 6.0e-03 |
| lung cancer | 2.100 | 1.7e-04 |
| lung carcinoma | -1.900 | 2.4e-23 |
| malignant mesothelioma | 5.900 | 1.5e-09 |
| osteosarcoma | -1.364 | 2.5e-05 |
| pancreatic cancer | 1.500 | 5.2e-06 |
| pediatric high grade glioma | 1.500 | 1.5e-05 |
| pituitary cancer | -1.700 | 1.0e-04 |
| psoriasis | -1.800 | 7.2e-05 |
| subependymal giant cell astrocytoma | 1.915 | 1.9e-02 |
MAPPPPPVLPVLLLLAAAAALPAMGLRAAAWEPRVPGGTRAFALRPGCTYAVGAACTPRAPRELLDVGRD 1 - 70 GRLAGRRRVSGAGRPLPLQVRLVARSAPTALSRRLRARTHLPGCGARARLCGTGARLCGALCFPVPGGCA 71 - 140 AAQHSALAAPTTLPACRCPPRPRPRCPGRPICLPPGGSVRLRLLCALRRAAGAVRVGLALEAATAGTPSA 141 - 210 SPSPSPPLPPNLPEARAGPARRARRGTSGRGSLKFPMPNYQVALFENEPAGTLILQLHAHYTIEGEEERV 211 - 280 SYYMEGLFDERSRGYFRIDSATGAVSTDSVLDRETKETHVLRVKAVDYSTPPRSATTYITVLVKDTNDHS 281 - 350 PVFEQSEYRERVRENLEVGYEVLTIRASDRDSPINANLRYRVLGGAWDVFQLNESSGVVSTRAVLDREEA 351 - 420 AEYQLLVEANDQGRNPGPLSATATVYIEVEDENDNYPQFSEQNYVVQVPEDVGLNTAVLRVQATDRDQGQ 421 - 490 NAAIHYSILSGNVAGQFYLHSLSGILDVINPLDFEDVQKYSLSIKAQDGGRPPLINSSGVVSVQVLDVND 491 - 560 NEPIFVSSPFQATVLENVPLGYPVVHIQAVDADSGENARLHYRLVDTASTFLGGGSAGPKNPAPTPDFPF 561 - 630 QIHNSSGWITVCAELDREEVEHYSFGVEAVDHGSPPMSSSTSVSITVLDVNDNDPVFTQPTYELRLNEDA 631 - 700 AVGSSVLTLQARDRDANSVITYQLTGGNTRNRFALSSQRGGGLITLALPLDYKQEQQYVLAVTASDGTRS 701 - 770 HTAHVLINVTDANTHRPVFQSSHYTVSVSEDRPVGTSIATLSANDEDTGENARITYVIQDPVPQFRIDPD 771 - 840 SGTMYTMMELDYENQVAYTLTIMAQDNGIPQKSDTTTLEILILDANDNAPQFLWDFYQGSIFEDAPPSTS 841 - 910 ILQVSATDRDSGPNGRLLYTFQGGDDGDGDFYIEPTSGVIRTQRRLDRENVAVYNLWALAVDRGSPTPLS 911 - 980 ASVEIQVTILDINDNAPMFEKDELELFVEENNPVGSVVAKIRANDPDEGPNAQIMYQIVEGDMRHFFQLD 981 - 1050 LLNGDLRAMVELDFEVRREYVLVVQATSAPLVSRATVHILLVDQNDNPPVLPDFQILFNNYVTNKSNSFP 1051 - 1120 TGVIGCIPAHDPDVSDSLNYTFVQGNELRLLLLDPATGELQLSRDLDNNRPLEALMEVSVSDGIHSVTAF 1121 - 1190 CTLRVTIITDDMLTNSITVRLENMSQEKFLSPLLALFVEGVAAVLSTTKDDVFVFNVQNDTDVSSNILNV 1191 - 1260 TFSALLPGGVRGQFFPSEDLQEQIYLNRTLLTTISTQRVLPFDDNICLREPCENYMKCVSVLRFDSSAPF 1261 - 1330 LSSTTVLFRPIHPINGLRCRCPPGFTGDYCETEIDLCYSDPCGANGRCRSREGGYTCECFEDFTGEHCEV 1331 - 1400 DARSGRCANGVCKNGGTCVNLLIGGFHCVCPPGEYERPYCEVTTRSFPPQSFVTFRGLRQRFHFTISLTF 1401 - 1470 ATQERNGLLLYNGRFNEKHDFIALEIVDEQVQLTFSAGETTTTVAPKVPSGVSDGRWHSVQVQYYNKPNI 1471 - 1540 GHLGLPHGPSGEKMAVVTVDDCDTTMAVRFGKDIGNYSCAAQGTQTGSKKSLDLTGPLLLGGVPNLPEDF 1541 - 1610 PVHNRQFVGCMRNLSVDGKNVDMAGFIANNGTREGCAARRNFCDGRRCQNGGTCVNRWNMYLCECPLRFG 1611 - 1680 GKNCEQAMPHPQLFSGESVVSWSDLNIIISVPWYLGLMFRTRKEDSVLMEATSGGPTSFRLQILNNYLQF 1681 - 1750 EVSHGPSDVESVMLSGLRVTDGEWHHLLIELKNVKEDSEMKHLVTMTLDYGMDQNKADIGGMLPGLTVRS 1751 - 1820 VVVGGASEDKVSVRRGFRGCMQGVRMGGTPTNVATLNMNNALKVRVKDGCDVDDPCTSSPCPPNSRCHDA 1821 - 1890 WEDYSCVCDKGYLGINCVDACHLNPCENMGACVRSPGSPQGYVCECGPSHYGPYCENKLDLPCPRGWWGN 1891 - 1960 PVCGPCHCAVSKGFDPDCNKTNGQCQCKENYYKLLAQDTCLPCDCFPHGSHSRTCDMATGQCACKPGVIG 1961 - 2030 RQCNRCDNPFAEVTTLGCEVIYNGCPKAFEAGIWWPQTKFGQPAAVPCPKGSVGNAVRHCSGEKGWLPPE 2031 - 2100 LFNCTTISFVDLRAMNEKLSRNETQVDGARALQLVRALRSATQHTGTLFGNDVRTAYQLLGHVLQHESWQ 2101 - 2170 QGFDLAATQDADFHEDVIHSGSALLAPATRAAWEQIQRSEGGTAQLLRRLEGYFSNVARNVRRTYLRPFV 2171 - 2240 IVTANMILAVDIFDKFNFTGARVPRFDTIHEEFPRELESSVSFPADFFRPPEEKEGPLLRPAGRRTTPQT 2241 - 2310 TRPGPGTEREAPISRRRRHPDDAGQFAVALVIIYRTLGQLLPERYDPDRRSLRLPHRPIINTPMVSTLVY 2311 - 2380 SEGAPLPRPLERPVLVEFALLEVEERTKPVCVFWNHSLAVGGTGGWSARGCELLSRNRTHVACQCSHTAS 2381 - 2450 FAVLMDISRRENGEVLPLKIVTYAAVSLSLAALLVAFVLLSLVRMLRSNLHSIHKHLAVALFLSQLVFVI 2451 - 2520 GINQTENPFLCTVVAILLHYIYMSTFAWTLVESLHVYRMLTEVRNIDTGPMRFYYVVGWGIPAIVTGLAV 2521 - 2590 GLDPQGYGNPDFCWLSLQDTLIWSFAGPIGAVIIINTVTSVLSAKVSCQRKHHYYGKKGIVSLLRTAFLL 2591 - 2660 LLLISATWLLGLLAVNRDALSFHYLFAIFSGLQGPFVLLFHCVLNQEVRKHLKGVLGGRKLHLEDSATTR 2661 - 2730 ATLLTRSLNCNTTFGDGPDMLRTDLGESTASLDSIVRDEGIQKLGVSSGLVRGSHGEPDASLMPRSCKDP 2731 - 2800 PGHDSDSDSELSLDEQSSSYASSHSSDSEDDGVGAEEKWDPARGAVHSTPKGDAVANHVPAGWPDQSLAE 2801 - 2870 SDSEDPSGKPRLKVETKVSVELHREEQGSHRGEYPPDQESGGAARLASSQPPEQRKGILKNKVTYPPPLT 2871 - 2940 LTEQTLKGRLREKLADCEQSPTSSRTSSLGSGGPDCAITVKSPGREPGRDHLNGVAMNVRTGSAQADGSD 2941 - 3010 SEKP 3011 - 3014 //
